1607 related articles for article (PubMed ID: 33294831)
1. Macrophage-derived thrombospondin 1 promotes obesity-associated non-alcoholic fatty liver disease.
Gwag T; Reddy Mooli RG; Li D; Lee S; Lee EY; Wang S
JHEP Rep; 2021 Feb; 3(1):100193. PubMed ID: 33294831
[TBL] [Abstract][Full Text] [Related]
2. Platelet-derived thrombospondin 1 promotes immune cell liver infiltration and exacerbates diet-induced steatohepatitis.
Gwag T; Lee S; Li Z; Newcomb A; Otuagomah J; Weinman SA; Liang Y; Zhou C; Wang S
JHEP Rep; 2024 Apr; 6(4):101019. PubMed ID: 38455470
[TBL] [Abstract][Full Text] [Related]
3. XBP1-mediated activation of the STING signalling pathway in macrophages contributes to liver fibrosis progression.
Wang Q; Bu Q; Liu M; Zhang R; Gu J; Li L; Zhou J; Liang Y; Su W; Liu Z; Wang M; Lian Z; Lu L; Zhou H
JHEP Rep; 2022 Nov; 4(11):100555. PubMed ID: 36185574
[TBL] [Abstract][Full Text] [Related]
4. Thrombospondin-I is a critical modulator in non-alcoholic steatohepatitis (NASH).
Min-DeBartolo J; Schlerman F; Akare S; Wang J; McMahon J; Zhan Y; Syed J; He W; Zhang B; Martinez RV
PLoS One; 2019; 14(12):e0226854. PubMed ID: 31891606
[TBL] [Abstract][Full Text] [Related]
5. Caspase-11 promotes high-fat diet-induced NAFLD by increasing glycolysis, OXPHOS, and pyroptosis in macrophages.
Drummer C; Saaoud F; Jhala NC; Cueto R; Sun Y; Xu K; Shao Y; Lu Y; Shen H; Yang L; Zhou Y; Yu J; Wu S; Snyder NW; Hu W; Zhuo J'; Zhong Y; Jiang X; Wang H; Yang X
Front Immunol; 2023; 14():1113883. PubMed ID: 36776889
[TBL] [Abstract][Full Text] [Related]
6. Stellate cell expression of SPARC-related modular calcium-binding protein 2 is associated with human non-alcoholic fatty liver disease severity.
Larsen FT; Hansen D; Terkelsen MK; Bendixen SM; Avolio F; Wernberg CW; Lauridsen MM; Grønkjaer LL; Jacobsen BG; Klinggaard EG; Mandrup S; Di Caterino T; Siersbæk MS; Indira Chandran V; Graversen JH; Krag A; Grøntved L; Ravnskjaer K
JHEP Rep; 2023 Feb; 5(2):100615. PubMed ID: 36687468
[TBL] [Abstract][Full Text] [Related]
7. Myeloid-specific deletion of thrombospondin 1 protects against inflammation and insulin resistance in long-term diet-induced obese male mice.
Memetimin H; Li D; Tan K; Zhou C; Liang Y; Wu Y; Wang S
Am J Physiol Endocrinol Metab; 2018 Dec; 315(6):E1194-E1203. PubMed ID: 30351986
[TBL] [Abstract][Full Text] [Related]
8. CD44 is a key player in non-alcoholic steatohepatitis.
Patouraux S; Rousseau D; Bonnafous S; Lebeaupin C; Luci C; Canivet CM; Schneck AS; Bertola A; Saint-Paul MC; Iannelli A; Gugenheim J; Anty R; Tran A; Bailly-Maitre B; Gual P
J Hepatol; 2017 Aug; 67(2):328-338. PubMed ID: 28323124
[TBL] [Abstract][Full Text] [Related]
9. Anti-CD47 antibody treatment attenuates liver inflammation and fibrosis in experimental non-alcoholic steatohepatitis models.
Gwag T; Ma E; Zhou C; Wang S
Liver Int; 2022 Apr; 42(4):829-841. PubMed ID: 35129307
[TBL] [Abstract][Full Text] [Related]
10. A blocking monoclonal antibody to CCL24 alleviates liver fibrosis and inflammation in experimental models of liver damage.
Segal-Salto M; Barashi N; Katav A; Edelshtein V; Aharon A; Hashmueli S; George J; Maor Y; Pinzani M; Haberman D; Hall A; Friedman S; Mor A
JHEP Rep; 2020 Feb; 2(1):100064. PubMed ID: 32039405
[TBL] [Abstract][Full Text] [Related]
11. Mitochondrial gene polymorphisms alter hepatic cellular energy metabolism and aggravate diet-induced non-alcoholic steatohepatitis.
Schröder T; Kucharczyk D; Bär F; Pagel R; Derer S; Jendrek ST; Sünderhauf A; Brethack AK; Hirose M; Möller S; Künstner A; Bischof J; Weyers I; Heeren J; Koczan D; Schmid SM; Divanovic S; Giles DA; Adamski J; Fellermann K; Lehnert H; Köhl J; Ibrahim S; Sina C
Mol Metab; 2016 Apr; 5(4):283-295. PubMed ID: 27069868
[TBL] [Abstract][Full Text] [Related]
12. Gasdermin D plays a key role as a pyroptosis executor of non-alcoholic steatohepatitis in humans and mice.
Xu B; Jiang M; Chu Y; Wang W; Chen D; Li X; Zhang Z; Zhang D; Fan D; Nie Y; Shao F; Wu K; Liang J
J Hepatol; 2018 Apr; 68(4):773-782. PubMed ID: 29273476
[TBL] [Abstract][Full Text] [Related]
13. Perilipin-2 promotes obesity and progressive fatty liver disease in mice through mechanistically distinct hepatocyte and extra-hepatocyte actions.
Orlicky DJ; Libby AE; Bales ES; McMahan RH; Monks J; La Rosa FG; McManaman JL
J Physiol; 2019 Mar; 597(6):1565-1584. PubMed ID: 30536914
[TBL] [Abstract][Full Text] [Related]
14. Role of XBP1 in regulating the progression of non-alcoholic steatohepatitis.
Wang Q; Zhou H; Bu Q; Wei S; Li L; Zhou J; Zhou S; Su W; Liu M; Liu Z; Wang M; Lu L
J Hepatol; 2022 Aug; 77(2):312-325. PubMed ID: 35292349
[TBL] [Abstract][Full Text] [Related]
15. TRIF Differentially Regulates Hepatic Steatosis and Inflammation/Fibrosis in Mice.
Yang L; Miura K; Zhang B; Matsushita H; Yang YM; Liang S; Song J; Roh YS; Seki E
Cell Mol Gastroenterol Hepatol; 2017 May; 3(3):469-483. PubMed ID: 28462384
[TBL] [Abstract][Full Text] [Related]
16. FGF21 protects against hepatic lipotoxicity and macrophage activation to attenuate fibrogenesis in nonalcoholic steatohepatitis.
Liu C; Schönke M; Spoorenberg B; Lambooij JM; van der Zande HJP; Zhou E; Tushuizen ME; Andreasson AC; Park A; Oldham S; Uhrbom M; Ahlstedt I; Ikeda Y; Wallenius K; Peng XR; Guigas B; Boon MR; Wang Y; Rensen PCN
Elife; 2023 Jan; 12():. PubMed ID: 36648330
[TBL] [Abstract][Full Text] [Related]
17. Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.
McGlinchey AJ; Govaere O; Geng D; Ratziu V; Allison M; Bousier J; Petta S; de Oliviera C; Bugianesi E; Schattenberg JM; Daly AK; Hyötyläinen T; Anstee QM; Orešič M
JHEP Rep; 2022 May; 4(5):100477. PubMed ID: 35434590
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-17 exacerbates hepatic steatosis and inflammation in non-alcoholic fatty liver disease.
Tang Y; Bian Z; Zhao L; Liu Y; Liang S; Wang Q; Han X; Peng Y; Chen X; Shen L; Qiu D; Li Z; Ma X
Clin Exp Immunol; 2011 Nov; 166(2):281-90. PubMed ID: 21985374
[TBL] [Abstract][Full Text] [Related]
19. Weight-loss-independent benefits of exercise on liver steatosis and stiffness in Japanese men with NAFLD.
Oh S; Tsujimoto T; Kim B; Uchida F; Suzuki H; Iizumi S; Isobe T; Sakae T; Tanaka K; Shoda J
JHEP Rep; 2021 Jun; 3(3):100253. PubMed ID: 33898958
[TBL] [Abstract][Full Text] [Related]
20. Hepatic stellate cells-specific LOXL1 deficiency abrogates hepatic inflammation, fibrosis, and corrects lipid metabolic abnormalities in non-obese NASH mice.
Yang A; Yan X; Fan X; Shi Y; Huang T; Li W; Chen W; Jia J; You H
Hepatol Int; 2021 Oct; 15(5):1122-1135. PubMed ID: 34014450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
